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ABSTRAK
Latar belakang: sudah banyak penelitian mengenai interferon-gamma release assay (IGRA) dalam TB luar 
paru, namun hanya sedikit yang berasal dari negara-negara berkembang. Ini merupakan penelitian pertama 
tentang kegunaan IGRA dalam TB luar paru yang dilakukan di Indonesia sebagai negara berkembang dengan 
kasus TB terbanyak kedua di dunia. Studi ini bertujuan untuk mengetahui manfaat pemeriksaan IGRA dalam 
mendiagnosis TB ekstraparu. Metode: sebanyak 84 pasien dengan dugaan TB ekstraparu dilakukan pemeriksaan 
IGRA dan pemeriksaan baku emas secara tersamar. Pemeriksaan baku emas dilakukan pemeriksaan histopatologi 
dan pewarnaan BTA jaringan. Hasil: dari total 84 pasien didapatkan hasil baku emas positif pada 57 pasien, 
dimana 50 pasien diantaranya didapatkan hasil IGRA positif. Dari 27 pasien dengan baku emas negatif 
didapatkan hasil IGRA positif pada 10 pasien. Limfadenitis TB merupakan manifestasi TB ekstraparu yang 
paling banyak ditemukan. Hasil uji diagnostik IGRA untuk TB ekstraparu yang didapat adalah sebagai berikut: 
sensitifitas 87,71%, spesifisitas 63%, nilai duga positif 83,33%, dan nilai duga negatif 70,83%. Kesimpulan: 
pemeriksaan IGRA dapat digunakan sebagai salah satu sarana penunjang diagnosis TB ekstraparu, namun 
hasil yang negatif belum dapat menyingkirkan kemungkinan adanya infeksi TB tersebut.
Kata kunci: TB ekstraparu, IGRA, histopatologi, BTA jaringan.
ABSTRACT
Background: there are many researches about IGRA in extrapulmonary Tuberculosis (TB), but there only 
few data from developing countries. This was the first research about the utility of IGRA in extrapulmonary TB 
performed in Indonesia as developing country with the 2nd most frequent of TB cases in the world. This study aimed 
to identify the advantage of IGRA examination in diagnosing extrapulmonary TB. Methods: eighty-four patients, 
presumed to have extrapulmonary TB were examined with IGRA and gold standard examination. The gold standard 
examination was performed by histopathologic examination, and tissue smear for acid-fast bacilli. Results: among 
84 patients included in the study, 57 patients were tested positive with gold standard, where 50 patients among 
them were also tested positive with IGRA. Among 27 patients tested negative with gold standard, IGRA positive 
was found in 10 patients. Lymphadenitis was the most common manifestation of the extrapulmonary TB. Diagnostic 
test from IGRA for extrapulmonary TB found as follows: sensitivity 87,71%, specificity 63%, positive predictive 
value 83,33%, and negative predictive value 70,83%. Conclusion: IGRA could be used as supporting tool in the 
diagnosis of extrapulmonary TB. The negative result, however, does not indicate absence of TB infection.
Keywords: extrapulmonary TB, IGRA, histopathology, tissue acid-fast bacilli.
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INTRODUCTION
Tuberculosis (TB) is still a global health 
problem. In 2016, it was estimated that there 
were 1.3 million deaths due to TB in non-HIV 
patients and 374.000 deaths in HIV patients. It 
was also estimated that there were 10.4 million 
TB patients in 2016, and 56% came from 5 
countries with the most-TB cases in the world, 
namely India, Indonesia, China, Philippines, and 
Pakistan.1 Although most of the patients suffered 
from pulmonary TB, about 15-25% suffered from 
extrapulmonary TB. Of all extrapulmonary TB 
patients, most cases commonly found were lymph 
node TB (35-40%), followed by pleural TB (20-
30%), bone and joint TB (5-10%), genitourinary 
TB (3-6.5%), tuberculous meningitis (5-6%), 
peritoneal TB (3%), and others (11.8%).2-6
Extrapulmonary TB is usually difficult to 
diagnose due to the unspecific symptoms, while 
the acid-fast bacilli smear and culture from 
tissue and body fluid often reveal negative result. 
Hence, an invasive procedure is usually required 
for histopathologic diagnosis.7,8 The International 
Standard for TB Care 2014 also suggested Gene-
Xpert MTB/RIF tissue examination to diagnose 
extrapulmonary TB. However such examination 
is still not feasible.7 The measurement of 
adenosine deaminase (ADA) level in body 
fluid is usually used as an alternative, although 
the utilization is still limited to pleural TB, 
pericardial TB and tuberculous meningitis.9 
Furthermore ADA level within the body fluid will 
also increase due to purulent bacteria infection, 
SLE or lymphoproliferative diseases.3
On the other hand, immunoassay staining 
to detect Mycobacterium tuberculosis-specific 
immune host response is becoming popular 
as alternative tools for extrapulmonary TB 
diagnosis. Mycobacterium tuberculosis (M.TB) 
will initiate cascade of immune respons which 
triggers cytokines secretion as well as Th1 
lymphocyte activation.  The level of interferon-γ 
(IFN- γ) as one of the cytokines produced by Th1 
cell, will increase due to M.TB infection. The 
Interferon-Gamma Release Assay (IGRA) aim 
to measure the level of IFN-γ released within the 
blood after being stimulated by purified protein 
derivate obtained from M.TB. Interferon-Gamma 
Release Assay in QuantiFERON Gold-In Tube 
assay (QFT-GIT) used 3 M.TB-specific antigens, 
namely early secreted antigenic target 6 (ESAT-
6), culture filtrate protein 10 (CFP 10) and TB7.7 
that only found in M.TB and not in either BCG 
strain or other nontuberculous mycobacteria.9 
The goal of this study is to investigate the benefit 
of IGRA with ELISA-based QuantiFERON-TB 
Gold In-Tube assay to diagnose extrapulmonary 
TB. There are many researches about IGRA in 
extrapulmonary TB, but most of them come 
from high-income countries and only a few 
from middle/low-income countries. This is the 
first research about the utility of IGRA in the 
diagnosis of extrapulmonary TB performed in 
Indonesia as developing country with the 2nd 
most frequent of TB cases in the world.
METHODS
This cross-sectional study was done in 
Cipto Mangunkusumo hospital. Samples were 
collected from October 2015-October 2017. This 
study had been approved by ethical clearance 
from the ethics committee Faculty of Medicine 
Universitas Indonesia on November 9th, 2015, 
with a reference number 976/UN2.F1/ETIK/2015.
Patients Selection
Samples were collected using consecutive 
methods, to include all patients suspected 
with extrapulmonary TB who came to the 
Pulmonology clinic and was admitted to Cipto 
Mangunkusumo Hospital. The inclusion criteria 
include over 18 year old patients, suspected 
with extrapulmonary TB but were not under any 
anti-tuberculosis medication, and consented to 
be subject of this study. The exclusion criteria 
include extrapulmonary TB patients with a 
homeostatic disturbance which prevents invasive 
intervention for tissue specimen collection. 
All patients who met the inclusion criteria 
underwent anamnesis, physical examination, 
routine laboratory, and radiologic examination 
according to the organ involvement. After that 
with blinding design IGRA examination from a 
blood specimen was performed to be compared 
with either histopathologic or tissue smear for 
acid-fast bacilli (AFB) as the gold standard. To 
obtain tissue specimen, a biopsy was performed 
through invasive intervention from the organs 
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involved. A positive result from biopsy indicates 
the presence of datia Langhans cell, epithelioid 
cell, granuloma with central caseous necrosis or 
AFB in the tissue.
ELISA-based QuantiFERON-TB Gold In-Tube 
Assay
Three ml blood sample was drawn and stored 
into 3 different tubes, namely Nil tube, TB antigen 
tube and mitogen tube. Tuberculosis antigen 
tube contains 3 kinds of TB-specific antigen 
coated on its wall namely ESAT-6, CFP-10, and 
RB7.7. The TB antigen tube was used to assess 
the IFN-g production by the T- lymphocyte in 
response to the TB-antigen. Mitogen tube contains 
phytohemagglutinin that could trigger lymphocyte 
cell proliferation, indicating the presence of a 
viable cell. After 1 ml blood sample was obtained, 
all tubes were shaken slowly for 5 seconds until 
the blood sample covered the inner layer of the 
tube wall. This step was performed to optimize 
the interaction between blood sample with the 
TB-antigens on the tube wall. All blood samples 
were sent to the laboratory to be incubated at 
370 C for 16-24 hours. After the incubation, all 
tubes were centrifuged in 2000-3000 g (RCF) 
for 15 minutes. Two hundred µL blood plasma 
was pipetted from the tube and added to the 
Quantiferon ELISA plate. Then, IGRA assay 
with ELISA was performed using the automated 
ELISA workstation. Data from IGRA were 
analyzed using Quaniferon Analysis Software.8
Interpretation
Results obtained from IGRA were reported 
qualitatively in 3 categories: positive, negative 
and indeterminate. A positive result was 
indicated by the difference between IFN-γ level 
in the TB antigen tube and in the Nil tube of 
≥ 0.35 IU. To control for the presence of non-
specific IFN-γ, the response in the TB-antigen 
tube must be more than 25% of the level of 
IFN-γ in the nil tube. The indeterminate result 
was indicated by no increase in the level of IFN-γ 
in the mitogen tube or when there was a high 
level of non-specific-IFN-γ in the nil tube (>8 
IU). Therefore re-examination was performed in 
indeterminate result. By implementing positive 
internal control (mitogen tube), the IGRA assay 
could differentiate indeterminate result from the 
true negative result.8
Data Analysis
The data analysis was done using SPSS 
20. Descriptive data were presented as the 
proportion of extrapulmonary TB and its clinical 
manifestation. The data were analyzed using 
2x2 chi-square test to determine sensitivity, 
specificity, positive predictive value (PPV), 
negative predictive value (NPV), positive 
likelihood ratio (PLR) and negative likelihood 
ratio (NLR) with 95% confidence interval (CI).
RESULTS
Out of  84 pat ients  suspected with 
extrapulmonary TB with median age of 33.5 
years (range 17-83 years), 57 patients were 
confirmed to have extrapulmonary TB based on 
gold standard examination. The characteristic of 
the subject and the type of extrapulmonary TB 
is shown in Table 1.
Table 1. Subject characteristic
Characteristic Total (N=84)
Age (years), median (range) 33.5 (17-83)
Gender (Male), n (%) 33 (39.3)
Positive gold standard, n (%)
 - Histopathology ( +) 56 (66.0)
 - Tissue smear for AFB (+) 1 (1.19)
Negative gold standard, n (%) 27 (32.1)
Extrapulmonary TB Type, n (%)
 - Lymph node TB 39 (46.2)
 - Cutaneus TB 9 (10.7)
 - Tuberculous spondylitis 3 (3.57)
 - Peritoneal TB 2 (2.38)
 - Tuberculous meningitis and 
lymph node TB 1 (1.19)
 - Tuberculous hepatitis 1 (1.19)
 - Genital TB 1 (1.19)
 - Renal TB 1 (1.19)
Most of the extrapulmonary TB patients were 
diagnosed based on histopathologic examination, 
with lymph node TB as the most frequent clinical 
manifestation. Twenty seventh patients were 
tested negative for extrapulmonary TB with gold 
standard examination. Most of them suffered from 
chronic non-specific lymphadenitis and metastatic 
lymph enlargement as shown in Table 2.
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Table 3 shows sensitivity, specificity, 
positive and negative predictive value, positive 
and negative likelihood ratio from IGRA 
compared to the gold standard.
of 87.7% (95% CI 77.0-94%) and 63.0% (95% 
CI 44.0-78%), respectively. Yun Feng et al.10 
found a better sensitivity and specificity values 
compared with our study namely 93.3% (95% 
CI 77.9- 99.2%) and 88.9% (95% CI 80-94.8%). 
However, in that study extrapulmonary TB 
was not entirely diagnosed based on the gold 
standard. In some patients, the presence of 
extrapulmonary TB was diagnosed only based on 
clinical symptoms and radiological features, thus 
affecting the validity of the study. Furthermore 
clinical manifestations of extrapulmonary TB 
in that study showed a different spectrum from 
our study; most of the patients (40%) exhibited 
central nervous system involvement, while 
lymph node involvement was only found in 10% 
of patients.10 In our study, lymph node TB was 
found in the majority of patients (46%), whereas 
tuberculous meningitis was only found in 1% of 
the patients.
The study from Oh-Hyung Cho et al.11 found 
a similar sensitivity value with our research, 
that is 84% (95% CI 78-89%), but with a 
lower specificity of 51% (95% CI 43- 58%). In 
that study, out of 153 patients (77.78%) were 
diagnosed with extrapulmonary TB based on 
gold standard, while the remaining 34 patients 
(22.22%) were diagnosed only based on clinical 
symptoms and response to anti-tuberculosis 
treatment. Moreover, the indeterminate results of 
IGRA examination which was found in 8 patients 
(5.2%) were directly included to the group with 
negative IGRA outcomes.11 Both of these would 
have affected research validity because in addition 
to the diagnosis problem that was not entirely 
accurate, the results of indeterminate IGRA was 
not necessarily negative. Indeterminate IGRA 
result means that the result cannot be concluded 
as negative or positive, which may result from 
errors in examination technique or may be due to 
severe immune deficiency.12,13 In severe immune 
deficiency there will be a significant decrease in 
CD4 cell count so that the production of IFN-g 
will also be greatly decreased. To determine, it 
should be re-examined with better examination 
technique. In our study, from 84 patients examined 
by IGRA, no indeterminate outcome was found.
Lin Fan et al.14 conducted a meta-analysis 
study with two different IGRA examination 
Table 2. Another extrapulmonary disease
Involved Organ N=27
Lymph, n (%)
 - Chronic non-specific lymphadenitis 10 (37.0)
 - Metastatic lymph enlargement 2 (7.40)
 - Kikuchi Fujimoto lymphadenitis 1 (3.70)
 - Epidermoid cyst 1 (3.70)
 - Sialadenosis 1(3.70)
Skin, n (%)
 - Hyperplasia epitheliomatosis 1 (3.70)
 - Actinomycosis 1 (3.70)
 - Achantocys epidermis 1 (3.70)
 - Chronic Ulcer 1 (3.70)
 - Epidermis cyst 1 (3.70)
Bone, n (%)
 - Chronic non-specific spondylitis 2 (7.40)
 - Chronic non-specific osteomyelitis 2 (7.40)
 - Others, n (%)
 - Chronic non-specific mastitis 2 (7.40)
 - Liver Cirrhosis 1 (3.70)
Table 3. Cross-tabulation of IGRA and gold standard
IGRA
Gold standard
Total
Positive Negative
Positive 50 10 60
Negative 7 17 24
Total 57 27 84
In this study, the sensitivity value of IGRA 
was 87.71% (95% CI 77.0-94,0%), while the 
specificity was 63.0% (95% CI 44.0-78%). 
Positive predictive value of IGRA was 83.33% 
(95% CI 72.0-91.0%), while negative predictive 
value was 70.83% (95% CI 51.0-85.0%). 
Positive likelihood ratio of IGRA was 2.37 
(1.39-4.02), while the negative likelihood ratio 
was 0.2 (0.09-0.41).
DISCUSSION
Among 84 patients suspected with 
extrapulmonary TB, 57 were definitively 
diagnosed with extrapulmonary Tb based on 
gold standard with sensitivity and specificity 
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techniques, namely the ELISA-based QFT-GIT 
and ELISpot-based T-SPOT.TB. In ELISpot-
based T-SPOT.TB the number of T cells that 
produce IFN-γ were calculated after exposure 
with all three antigens as in QFT-GIT. The QFT-
GIT pooled sensitivity and specificity were 72% 
(95% CI 65-79%) and 82% (95% CI 78-87%), 
respectively. T-SPOT.TB showed a better pooled 
sensitivity value of 90% (95% CI 86-93%), 
but a lower pooled specificity of 68% (95% CI 
64-73%). In this study, subgroup analysis was 
performed based on patient’s economic level. 
Sensitivity and specificity values were still 
good enough in high-income countries namely 
79-89% and 73-83%, respectively; but in low/
middle-income countries, lower values were 
obtained (29% with QFT-GIT and 34% with 
T-SPOT.TB).14 There were some limitations 
in that meta-analysis, because 17 from 20 
selected original studies were from high-income 
countries and only 3 studies from low/middle-
income countries.14 Also, although the clinical 
manifestations of extrapulmonary TB in that 
study included a variety of organ involvement, 
research on low/middle-income countries. 
Involved only one organ system, each of which 
is pleura and meninges. This is different from our 
study that showed involvement of various organ 
systems with the most frequent manifestation 
being lymph node TB. The sensitivity of IGRA 
was influenced by antigen levels, host response 
to its antigen and the manifestations of organ 
involvement. With higher antigen level that 
marked by high levels of ESAT-6, CFP-10, 
and TB7.7 produced by genes in the region of 
difference-1 (RD1), the formed immune response 
will be stronger. In lymph node TB, high levels 
of antigen are obtained with a good immune 
response so that lymphocyte cells will produce 
IFN-γ efficiently. In contrast to tuberculous 
meningitis, low levels of antigen are found with 
low to moderate levels of host immune responses 
so that IFN-γ production by lymphocytes also 
becomes lower.11 This may explain why in 
this meta-analysis, when subgroup analysis is 
obtained, low sensitivity and specificity values 
were found in low/middle-income countries. In 
addition, blinding design which is a required 
in diagnostic research was only performed in 5 
original research.
Shin JA et al.15 obtained a lower sensitivity 
value than our study of 70.2% (95% CI 63.7-
74.8%) with a similar specificity of 66.7% 
(95% CI 32.9-90.6%). In subgroup analysis 
based on the organs involvement, sensitivity 
and specificity of IGRA in lymph node TB were 
better namely 81.8% (95% CI 61.4-90.4%) 
and 80% (95% CI 35.1-98.9%). Contrastingly, 
pleural TB has lower values of 38.5% (95% CI 
31.25-45.7%) and 50% (95% CI 2.7- 97.3%).15 
Based on this study, IGRA in extrapulmonary TB 
is particularly useful in diagnosing lymph node 
TB compared with tuberculosis that affect other 
extrapulmonary organs.15
Adilistya et al.16 conducted a study using 
IGRA on pleural fluid with T-SPOT.TB to 
diagnose pleural TB. Sensitivity and specificity 
value from that study were 100% (95% CI 97-
100%) and 88.89% (95% CI 51.75-99.72%), with 
PPV and NPV of 97.5% (95% CI 86.84-99.94%) 
and 100% (95% CI 63-100%), respectively. 
Although IGRA’s diagnostic performance was 
much better than our study, there was a limitation 
that could affect study validity. This limitation 
was related to cut-off value for IGRA positivity in 
pleural fluid. In that study, IGRA test on pleural 
fluid was considered positive when there was ≥ 
6 spot-forming units (SFU), which described the 
number of active T cells producing IFN-γ.16 Until 
now there is no standard IGRA cut-off value for 
T-SPOT.TB in pleural fluid. Xiao-Xia Zhou et 
al.17 in their meta-analysis also obtained a good 
pooled sensitivity and specificity of T-SPOT.TB 
for pleural liquid, 92% (95% CI 88-95%) and 
85% (95% CI 78-91%), without using standard 
IGRA cut-off value. The current cut-off value 
for IGRA in pleural fluid is provided only for 
QFT-GIT, which varies in value from 0.3 U/L 
to 10 U/L.8
Other meta-analysis studies were also 
performed by Qianqian Liu et al.18 that were 
conducted in patients suspected with lymph 
node TB. From 10 selected original research, 
the pooled sensitivity and pooled specificity 
were 89% (95% CI 85-92%) and 81% (95% 
CI 77-83%), respectively. Extrapulmonary TB 
diagnosis in this meta-analysis were also not 
entirely based on the gold standard. In some 
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patients, the diagnostic criteria were based 
on the clinical response to anti-tuberculosis 
treatment.18 Although that meta-analysis study 
shows similar sensitivity to our research and 
even with better specificity values, since it only 
involved one organ, it was less likely to describe 
extrapulmonary TB clinical spectrum in daily 
practice.
There is a limitation in our study. From 
84 patients enrolled, none of them showed 
any pleural involvement. This is because for 
diagnosing pleural TB there is currently available 
a safer and less invasive diagnosis modalities, 
with a good sensitivity and specificity namely 
ADA examination. Adenosine deaminase 
cut-off value for pleural TB is > 40 U/L with 
sensitivity and specificity of 89-99% and 88-
97%, respectively.8 The availability of ADA 
examination results in a pleural biopsy performed 
by pleuroscopy becomes overly invasive, 
requiring more expensive costs, and a higher 
risk of intervention.
CONCLUSION
The IGRA examination that is used to 
diagnose extrapulmonary TB shows good 
sensitivity and PPV of 87.7% and 83.3%, 
respectively, therefore IGRA examination can 
be used as a supporting tool for diagnosis. A low 
specificity value (63%) indicates that negative 
IGRA results cannot exclude possibilities of 
extrapulmonary TB. Other modalities are still 
needed to confirm presenting of extrapulmonary 
TB with either non-invaive or invasive measure.
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